TuHURA Advances VISTA Inhibitor into AML Trials with FDA IND Filing
Event summary
- TuHURA Biosciences filed an Investigational New Drug (IND) application with the FDA for its TBS-2025 VISTA-inhibiting antibody to treat molecularly defined subsets of AML and other blood-related cancers.
- The IND filing follows detailed FDA guidance on the development pathway for both monotherapy and combination with menin inhibitors for AML.
- TuHURA plans to initiate a Phase 1b/2 study in the second half of 2026, targeting relapsed/refractory AML patients with NPM1 mutations.
- TBS-2025 demonstrated a favorable safety profile in a previous Phase 1 trial in solid tumors, with data informing the design of the upcoming AML trial.
The big picture
TuHURA's advancement of TBS-2025 into AML trials positions the company at the forefront of targeting VISTA, a novel checkpoint in hematologic cancers. The strategic focus on molecularly defined subsets of AML, particularly those with NPM1 mutations, aligns with the broader industry trend toward precision oncology. The potential to combine TBS-2025 with menin inhibitors could create a differentiated therapeutic approach in a space with limited effective treatments.
What we're watching
- Regulatory Pathway
- Whether the FDA's written responses will support TuHURA's proposed Phase 1b/2 study design and accelerate the development timeline.
- Clinical Efficacy
- How TBS-2025 performs in combination with menin inhibitors in improving complete response rates and duration of response in mutNPM1 relapsed/refractory AML.
- Market Opportunity
- The pace at which TuHURA can address the significant unmet medical need in molecularly defined subsets of AML and other blood-related cancers.
Related topics